Women's Health, Phase III

Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis (PREGnant)

Volunteers
Health Professionals

What is the purpose of this trial?

A Phase 3 randomized clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is that in infertile woman with endometriosis undergoing in vitro fertilization-embryo transfer (IVF-ET), live birth rates will improve in those pretreated with GnRH antagonist compared to placebo.

Trial with
Yale University School of Medicine and National Institute of Child Health and Human Development (NICHD)
Ages
18 years - 38 years
Gender
Female only

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Michele Frank

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Hugh Taylor, MD
Anita O'Keeffe Young Professor of Obstetrics, Gynecology, and Reproductive Sciences and Professor of Molecular, Cellular, and Developmental Biology; Chair, Obstetrics, Gynecology & Reproductive Sciences; Chief , Obstetrics and Gynecology, Yale New Haven Hospital

Sub-Investigators

Last Updated
07/02/2024
Study HIC
#2000027121